NCT00823121

Brief Summary

Cryopreservation of all embryos and transferring them subsequently in assisted reproductive technology (ART) cycles to improve outcome.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Aug 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2008

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 14, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 15, 2009

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2009

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

January 20, 2010

Status Verified

April 1, 2009

Enrollment Period

6 months

First QC Date

January 14, 2009

Last Update Submit

January 19, 2010

Conditions

Keywords

Fresh embryo transferfrozen- thawed embryo transfervitrificationendometrial receptivityimplantation ratepregnancyART

Outcome Measures

Primary Outcomes (1)

  • implantation rate

    4 weeks

Secondary Outcomes (1)

  • on going pregnancy rate

    3 months

Study Arms (2)

frozen-embryo transfer

ACTIVE COMPARATOR

In this group all embryos are cryopreserved and two months later embryo transfer will perform.

Procedure: freezing embryos by vitrificationDrug: buserelinDrug: recombinant FSHDrug: human chorionic gonadotropin (pregnyl)

fresh embryo transfer

ACTIVE COMPARATOR

In this arm fresh embryo transfers are performed on day 2 or 3.

Procedure: fresh embryo transfersDrug: buserelinDrug: recombinant FSHDrug: human chorionic gonadotropin (pregnyl)

Interventions

vitrification by Cryotop method

Also known as: cryopreservation of embryos
frozen-embryo transfer

fresh embryo transfers

Also known as: embryo transfer using fresh embryos
fresh embryo transfer

Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.

Also known as: suprefact
fresh embryo transferfrozen-embryo transfer

gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle

Also known as: Gonal F
fresh embryo transferfrozen-embryo transfer

hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.

Also known as: pregnyl
fresh embryo transferfrozen-embryo transfer

Eligibility Criteria

Age18 Years - 38 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • age \< 38
  • normal day 3 FSH
  • classified as high risk for OHSS
  • has ≥ 15 follicles with a mean diameter ≥ 12 mm per each ovary
  • E2 levels on the day of hCG administration \> 3000 pg/mL
  • undergoing her first assisted reproduction treatment cycle

You may not qualify if:

  • who does not have good-quality embryos appropriate for cryopreservation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

: Research and clinical center for infertility

Yazd, Yazd Province, 8916877391, Iran

RECRUITING

Related Publications (1)

  • Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Can fresh embryo transfers be replaced by cryopreserved-thawed embryo transfers in assisted reproductive cycles? A randomized controlled trial. J Assist Reprod Genet. 2010 Jul;27(7):357-63. doi: 10.1007/s10815-010-9412-9. Epub 2010 Apr 6.

MeSH Terms

Interventions

Buserelinfollitropin alfaChorionic Gonadotropin

Intervention Hierarchy (Ancestors)

Gonadotropin-Releasing HormonePituitary Hormone-Releasing HormonesHypothalamic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteinsGonadotropinsPlacental HormonesPregnancy Proteins

Study Officials

  • abbas aflatoonian, M.D.

    Research and Clinical Center for Infertility

    PRINCIPAL INVESTIGATOR
  • homa oskouian, M.D.

    Research and Clinical Center for Infertility

    PRINCIPAL INVESTIGATOR

Central Study Contacts

homa oskouian, Dr

CONTACT

abbas aflatoonian, Dr

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 14, 2009

First Posted

January 15, 2009

Study Start

August 1, 2008

Primary Completion

February 1, 2009

Study Completion

December 1, 2009

Last Updated

January 20, 2010

Record last verified: 2009-04

Locations